drugset / Trial / NCT04884009
A Trial of SHR-1701 in Combination With and Without Famitinib Malate in Patients With Extensive Stage Small Cell Lung Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The study is being conducted to evaluate the efficacy and safety of SHR-1701 in combination with or without famitinib malate for the treatment of extensive stage small cell lung cancer after the failure of previous systemic chemotherapy
Timeline
- Start
- 2021-05-31
- Primary completion
- 2022-12-31
- Completion
- 2022-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Famitinib | Small molecule | — | — |
| Subject | Retlirafusp alfa | Protein / enzyme biologic | — | — |